CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (1,403,411)	$ (16,966,455)
Adjustments to reconcile net income to cash used in operating activities, net of acquisitions
Stock based compensation expense	124,599	88,214
Depreciation and amortization	2,885,457	1,556,982
Payment-in-kind interest	0	577,440
Rent paid by common stock	244,000	0
Gain on sale of assets	(9,748,562)	0
Loss on sale of assets	46,725	70,478
Increase in fair value of derivative liability	1,986,320	0
Deferred federal income tax expense/(gain)	0	5,306,000
Changes in operating assets and liabilities
Accounts receivable	2,637,258	(418,097)
Allowance for doubtful accounts	0	2,650,000
Inventory	(1,016,556)	1,095,357
Prepaid expenses	428,958	(364,309)
Costs in excess of billings	0	779,285
Accounts payable and accrued expenses	(3,770,626)	661,617
Deferred revenue	722,789	2,447,730
Net cash used in operating activities	(6,863,049)	(2,515,758)
Cash flows from investing activities
Purchase of fixed assets	(1,216,916)	(312,659)
Proceeds from sale of Bango assets	29,788,114	4,500
Costs related to sale of Bango assets	(10,792,446)	0
Establish escrow account - restricted cash	(1,500,000)	0
Proceeds from sale of Bango assets	20,900	0
Net cash provided by (used in) investing activities	16,299,652	(308,159)
Cash flows from financing activities
Proceeds from sale of Series C Preferred stock	4,000,000	0
Payments on other short and long-term debt	5,366,584	0
Payments on notes payable	(16,592,492)	(449,818)
Proceeds from revolving note	20,720,000	1,437,500
Payments on revolving note	(21,913,664)	0
Notes receivable	0	(500,000)
Net cash provided by (used in) financing activities	(8,419,572)	487,682
Net change in cash and cash equivalents	1,017,031	(2,336,235)
Cash and cash equivalents at beginning of the period	765,364	6,017,076
Cash and cash equivalents at end of period	1,782,395	3,680,841
SUPPLEMENTAL INFORMATION
Cash paid for interest	474,573	953,115
Cash paid (received) for income tax expense (benefit)	(117,646)	0
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Conversion of Series A Preferred Stock into common stock	120	17
Accretion of discount on Series B Preferred stock	386,658	0
Series B Preferred dividends accrued	$ 373,706	$ 0